SECuRE update: 8 GBq Cu-67 SAR-bisPSMA dose level with two additional complete responses
Sydney, Australia 5 August 2026 Highlights Preliminary assessment of the 8 GBq 67Cu-SAR-bisPSMA dose cohorts Nineteen participants from the SECuRE trial (NCT04868604)1 were included in this assessment of the safety and efficacy of the 8 GBq 67Cu-SAR-bisPSMA dose level. This includes 3 participants from cohort 2 of the Dose Escalation phase and 16 participants from…